Systemic, Targeted, & Immune Therapies
-
PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays
By Fred R. Hirsch, MD, PhD Posted: April 2018 Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of its refinement, we struggle […]
-
PACIFIC Trial Leads to Durvalumab Approval in United States
The U.S. Food and Drug Administration approved durvalumab on February 16, 2018, for the treatment of patients with stage III NSCLC whose tumors are unresectable and whose cancer has not […]
-
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC
By Hossein Borghaei, MS, DO Posted: February 2018 The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For patients who are treatment […]
-
ALK Testing in Europe
By Enriqueta Felip, MD, PhD Posted: February 2018 ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with stage IV adenocarcinomas of […]
-
Immunotherapy Adverse-Event Treatment Resource Guide
The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline to support nurses and allied health […]
-
Management of Immunotherapy Toxicity in NSCLC
By Beth Eaby-Sandy, MSN, CRNP Posted: February 2018 When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was focused and streamlined. Chemotherapy […]
-
ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer
By Heather Wakelee, MD Posted: October 2017 For most of the world, four cycles of cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II and […]
-
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations
By Cynthia L. Kryder, MS, CCC-Sp Editor Note: IASLC Lung Cancer News is pleased to provide the following overview, which is followed by expert commentary by Dr. Heather Wakelee, Dr. […]
-
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations
By Julien Mazieres, MD, PhD Posted: October 2017 The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The deciphering of lung oncogenesis […]
-
Q & A with Yi-Long Wu, MD
What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally?Posted: October 2017 Current Chinese Lung Cancer Diagnosis and Treatment Guideline […]
View ILCN Archives
Provider Resources